Kristin Brooks, Contract Pharma10.14.14
Outsourcing of pharma and biopharma contract services has grown exponentially during the past 15 years, influenced by numerous industry events and circumstances such as increased regulatory challenges, unique manufacturing needs, pharma/biopharma mega mergers, as well as the erosion of the blockbuster era. Contract Pharma looks at changes in the industry and outsourcing, what it looked like then, how it has evolved, and where it is today. Additionally, a diverse range of contract service providers offers their thoughts on how business operations have evolved to accommodate changing industry needs.
Looking Back
Several key drugs have influenced and transformed the industry over the years, including Merck’s infamous painkiller Vioxx, which redefined drug safety oversight and post approval studies, and Pfizer’s original blockbuster Lipitor, that in 2006 peaked at $13.7 billion in sales. Additionally, biologic breakthroughs such as Abbott’s Humira (now Abbvie), Roche/Genentech’s Rituxan, and Amgen’s Enbrel, helped pave the way for burgeoning biopharma development and countless drug approvals.
Looking Back
Several key drugs have influenced and transformed the industry over the years, including Merck’s infamous painkiller Vioxx, which redefined drug safety oversight and post approval studies, and Pfizer’s original blockbuster Lipitor, that in 2006 peaked at $13.7 billion in sales. Additionally, biologic breakthroughs such as Abbott’s Humira (now Abbvie), Roche/Genentech’s Rituxan, and Amgen’s Enbrel, helped pave the way for burgeoning biopharma development and countless drug approvals.
Continue reading this story and get 24/7 access to Contract Pharma for FREE
FREE SUBSCRIPTION
